Browse drugs

…ivation profile relying on the activation of JAK/STAT pathways. Tofacitinib, a pan-JAK inhibitor, down regulates interferon (IFN) in human …

…es (PROs) in patients with rheumatoid arthritis (RA) initiating tofacitinib in a real-world setting.Design The non-interventional study ESC…

…tinib on clinical biomarkers and quality of life; and safety of tofacitinib use for treatment of chronic pouchitis. Study period is up to t…

…CT00661661 and ORAL Sequel) assessed time to discontinuation of tofacitinib treatment.Results At baseline, female patients had similar DAS2…

…the pharmacokinetics, effectiveness, safety and tolerability of tofacitinib in young adults with active mucocutaneous (MC) SLE manifestatio…

…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…

…ith refractory CS or probable CS treated with the JAK inhibitor tofacitinib at the University Hospital Zurich from 2020 to 2024. Treatment …

… JAK inhibitors-related AERs extracted from the FAERS database. Baricitinib was associated with an elevated risk of cardiac disorders (ROR=…

…licated autoimmune disease characterized by recurrent relapses. Belimumab (BEL) is a humanized monoclonal antibody and has been approved …

… biochemical parameters. Budesonide and prednisone were weaned. Tofacitinib continues.Conclusions CD20+ cells play a regulatory and protect…

…ngle-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rit…

…citinib or upadacitinib), rituximab, tocilizumab, methotrexate, mycophenolate mofetil, or glucocorticoids (>=10 mg prednisone equivalent daily) for m…